Form 4: Neuronetics Executive VP Macan Reports Stock Sales and RSU Award

William Andrew Macan, EVP, GC, CCO and CS of Neuronetics, Inc., reports selling shares to cover tax obligations and receiving a new restricted stock unit (RSU) award.

Summary

• On February 28, 2024, William Andrew Macan sold 22,377 shares of Neuronetics, Inc. common stock at a weighted average price of $3.16 per share to satisfy tax obligations related to vesting RSUs.
• On February 29, 2024, Macan sold an additional 6,026 shares at a weighted average price of $2.94 per share, also for tax obligations.
• On the same day, Macan was granted 15,000 restricted stock units (RSUs) that vest in three equal annual installments starting February 28, 2025, contingent upon continued service.
• Following these transactions, Macan directly owns 404,333 shares of Neuronetics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The stock sales are for tax obligations, which is a normal occurrence. The RSU grant is a positive sign of continued investment in the executive.

Positives

• The RSU award of 15,000 shares demonstrates continued investment in the company by compensating key personnel.
• The vesting schedule of the RSU award encourages long-term commitment from the executive.

Negatives

• The sale of shares by an executive, even for tax purposes, could be perceived negatively by some investors.

Risks

• Executive stock sales, even for tax purposes, can sometimes create short-term downward pressure on the stock price.
• The vesting of the RSU award is contingent on continued service, creating a potential risk if the executive leaves the company before full vesting.

Future Outlook

The RSU award vests in three equal annual installments beginning on February 28, 2025, subject to continuous service.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. RSU grants are a typical form of executive compensation used to align management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including RSU grants, are common in the medical device industry.
• The vesting schedule of the RSU award is typical, with annual installments over a three-year period.
• Stock sales to cover tax obligations are a routine part of executive compensation.

Stakeholder Impact

• Shareholders may be interested in the executive's stock transactions as an indicator of management's confidence in the company.
• Employees may view the RSU grant as a positive sign of the company's commitment to its leadership.

Key Dates